Tiger Brokers

BRIEF-NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer

Reuters
Mar 16
BRIEF-NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer

March 16 (Reuters) - NovaBridge Biosciences NBP.O:

  • NOVABRIDGE ANNOUNCES PRODUCTIVE FDA TYPE B MEETING ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR GIVASTOMIG IN GASTRIC CANCER

  • NOVABRIDGE BIOSCIENCES - FDA CONFIRMS GIVASTOMIG ELIGIBLE FOR ACCELERATED APPROVAL PATHWAY

  • NOVABRIDGE BIOSCIENCES - TO INITIATE REGISTRATIONAL PHASE 3 COMBINATION TRIAL IN Q4 2026 USING ORR AS PRIMARY ENDPOINT

Source text: ID:nGNX4zrx9d

Further company coverage: NBP.O

((((Reuters.Briefs@thomsonreuters.com;));))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10